TTY Biopharm Co

TTY Biopharm Co Current Assets

The Current Assets of TTY Biopharm Co (4105.TWO) as of Nov 4, 2026 is 1.40 B TWD. In the previous year, Current Assets was 2.65 B TWD — a change of -47.14% (lower).

Current Assets

1.40 BTWD

YoY

-47.14%

Last updated:

Current Assets of TTY Biopharm Co is 2025 1.40 B TWD. Current Assets of TTY Biopharm Co was 2024 2.65 B TWD. It decreases by -47.14% lower compared to the previous year.

The TTY Biopharm Co Current Assets history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Current Assets
Date
Current Assets
Jan 1, 2018
1.73 B TWD
Jan 1, 2019
2.02 B TWD
Jan 1, 2020
4.73 B TWD
Jan 1, 2021
4.70 B TWD
Jan 1, 2022
4.99 B TWD
Jan 1, 2023
5.29 B TWD
Jan 1, 2024
2.65 B TWD
Jan 1, 2025
1.40 B TWD
The TTY Biopharm Co Current Assets history
YEARCurrent AssetsYoY
1.40 BTWD-47.14%
2.65 BTWD-49.85%
5.29 BTWD+6.14%
4.99 BTWD+6.02%
4.70 BTWD-0.67%
4.73 BTWD+134.22%
2.02 BTWD+16.99%
1.73 BTWD-2.28%
1.77 BTWD-62.13%
4.67 BTWD+8.54%
4.30 BTWD+62.13%
2.65 BTWD-7.29%
2.86 BTWD-18.63%
3.52 BTWD+16.58%
3.02 BTWD+11.41%
2.71 BTWD+30.31%
2.08 BTWD+7.27%
1.94 BTWD+5.71%
1.83 BTWD+8.70%
1.69 BTWD-16.99%
2.03 BTWD+15.53%
1.76 BTWD+28.74%
1.37 BTWD+21.02%
1.13 BTWD+141.89%
466.40 MTWD—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

TTY Biopharm Co Stock analysis

What does TTY Biopharm Co do? TTY Biopharm Co Ltd generates revenue through pharmaceutical and chemical drug production, primarily targeting domestic and overseas markets. The company's six business segments include Cancer Drug, Healthcare, Anti-Infective Drug, Domestic Cardiovascular and Gastrointestinal Drug, Mainland Medical Drug, and Other segments. Key products are oncology medicines such as anti-cancer and auxiliary drugs, anti-infective medicines like back-line antimicrobial agents and influenza vaccines, and healthcare medicines covering gastrointestinal, bone, metabolic health care, and infection treatment. Domestic and overseas customers purchase these products through the company's distribution channels. The Cancer Drug segment focuses on oncology medicines, including anti-cancer and auxiliary drugs, while the Anti-Infective Drug segment offers back-line antimicrobial agents and influenza vaccines. Healthcare segment products target gastrointestinal, bone, and metabolic health care, alongside infection treatment drugs. Mainland Medical Drug segment serves the mainland market with medical drugs, and Other segment handles additional product lines. All products are distributed domestically and internationally. Domestic and overseas markets drive sales of TTY Biopharm's pharmaceutical portfolio. Customers include healthcare providers and distributors purchasing oncology, anti-infective, and healthcare medicines. The Mainland Medical Drug segment specifically caters to the mainland market, while other segments serve broader regional demands. Product distribution spans both local and global channels. TTY Biopharm Co is one of the most popular companies on Eulerpool.

Frequently Asked Questions about TTY Biopharm Co stock

Current Assets of TTY Biopharm Co is 1.40 B TWD in 2025.

Current Assets of TTY Biopharm Co changed from 2.65 B TWD to 1.40 B TWD, representing a -47.14% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Current Assets TTY Biopharm Co since 2006 – with annual values, charts, and detailed analysis.

Current assets are assets expected to be converted to cash within one year, including cash, receivables, and inventory.

Current Assets's TWD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Current Assets's TTY Biopharm Co historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Balance Sheet — TTY Biopharm Co

All Key Metrics — TTY Biopharm Co